Enzymlogic are experts in the characterization of molecular mechanism of drug action and binding kinetics, to promote the design of innovative drugs
Tom Meek is a world leader in enzymology applied to drug discovery and a founding father of the drug-target residence time concept. Since his early publication on the subject in Nature in 2004, the importance of kinetics in drug-target interactions has been increasingly recognized to play a pivotal role in determining both the efficacy and toxicity of a drug.
During his 17 years as VP at GSK, Tom provided worldwide scientific and strategic leadership in assay development for all early-phase drug discovery programs. He is currently Professor in the Department of Biochemistry & Biophysics at Texas A&M University where he conducts detailed studies on enzyme mechanisms, to develop rationally-designed drugs targeting these enzymes.
His passion for kinetics and deep knowledge of enzymology has been fundamental to shaping Enzymlogic’s business and driving it forward.